SHENZHEN, China – Fapon Biotech, a leader in the In-vitro Diagnostics (IVD) sector, is taking significant steps to enhance global health through innovative diagnostic solutions. Following the World Health Organization’s announcement of monkeypox as a public health emergency of international concern on August 14, Fapon Biotech has reinforced its dedication by launching antigen diagnostic products specifically targeting this emerging health threat.
In response to the monkeypox outbreak that began in 2022, Fapon Biotech has persistently advanced its raw materials for monkeypox antigen rapid tests. The company’s detection products showcase high sensitivity and specificity, ensuring no cross-reactivity with unrelated viruses, including the varicella-zoster virus. Fapon’s solutions are designed to provide more efficient and accessible testing options, especially in low- and middle-income countries, facilitating quicker diagnoses in those regions.
The rise in global monkeypox cases in 2023 has further underscored the urgent demand for diagnostics, demonstrating the necessity for streamlined, automated, and accessible assays operable outside of traditional laboratory settings. To address this need, the WHO has introduced a target product profile aimed at decentralized use, promoting testing in community environments. This initiative has spurred more IVD companies to create point-of-care testing (POCT) solutions that are convenient and accessible for screening in underserved areas.
Fapon Biotech remains committed to utilizing its expertise to combat the monkeypox outbreak and assist its partners in developing rapid diagnostic tests for the virus.
With over 20 years of experience, Fapon Biotech has played an essential role in crafting IVD solutions that mitigate the spread of various infectious diseases, including HIV, hepatitis C, syphilis, malaria, dengue, and respiratory infections.
Looking ahead, Fapon Biotech’s extensive knowledge in antibody design and innovative technology positions it to support the development of diagnostic tests that enable earlier detection and treatment initiation, ultimately enhancing public health outcomes.
